Stefan Luzi


Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical and life science instruments sectors. He led the investment in Lava Therapeutics B.V. and was part of several other investments. He represents Gilde on the boards of Lava Therapeutics B.V. and Lumicks B.V.

Prior to joining Gilde, Stefan worked at Merck KGaA where he completed several international assignments including the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono's innovation competitions.

Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), where he developed a bicyclic peptide-based drug discovery platform.

He is a Swiss citizen based in Gilde's Utrecht office.

+31 30 219 2565